TABLE 1.
Demographics, clinical features, and diagnostic data of study participants with Buruli ulcer who received rifampin orally and streptomycin intramuscularly daily for 2 weeks followed by rifampin and clarithromycin orally each day for 6 weeksa
| Patient parameter | RS2RC6 value(s) |
|---|---|
| Total no. | 43 |
| Sex (no. of males/no. of females) | 18/25 |
| Median (range) age (yr) | 14 (5–70) |
| No. (%) with indicated site of lesion | |
| Head and neck | 1 (2) |
| Upper limbs | 21 (49) |
| Trunk | 1 (2) |
| Lower limbs | 20 (47) |
| No. (%) with indicated clinical form of lesion | |
| Nodule | 14 (32) |
| Plaque | 9 (21) |
| Ulcer | 20 (47) |
| No. (%) with indicated category of lesion | |
| I | 27 (63) |
| II | 12 (28) |
| III | 4 (9) |
| No. with indicated laboratory confirmation result | |
| AFB detectionb (+/−) | 11/21 |
| M. ulcerans culturec (+/−) | 14/22 |
| PCR for IS2404 (+/−) | 43/0 |
a
RS2RC6, administration of rifampin orally and streptomycin intramuscularly daily for 2 weeks followed by administration of rifampin and clarithromycin orally each day for 6 weeks. +, positive result; −, negative result.
b
Zeihl-Neelsen staining for acid-fast bacilli (AFB) was not performed at baseline in 11 patients.
c
M. ulcerans culture was not performed at baseline in 7 patients.